Glaucoma Related Quality of Life Study
This observational study is looking at how glaucoma and its treatments affect your quality of life. Researchers will ask you to complete several questionnaires, including the GQL-15, Glaucoma Symptom Scale (GSS), NEI Vision Function Questionnaire, and Ocular Surface Disease Index (OSDI). These questionnaires help understand your symptoms and how well you see. You can join if you have been diagnosed with glaucoma (open- or closed-angle, primary or secondary) and are 18 years or older. The study aims to understand how your quality of life changes after starting glaucoma treatment (like eye drops, SLT laser, or surgery). We don't know the current enrollment status, but the study plans to include 5000 participants.
- Study design
- This is an observational study, meaning researchers will collect information without giving you a specific treatment. It plans to include 5000 participants.
- What's involved
- You would complete several quality of life questionnaires at the beginning of the study and again 3-6 months after starting glaucoma treatment.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your quality of life will be assessed at baseline and again 3-6 months after your glaucoma treatment begins.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Glaucoma Related Quality of Life
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Ocular Surface Disease Index (OSDI)At baseline and 3-6 months after glaucoma treatment (i.e. drops, SLT, or surgery) was initiated/performed.
The OSDI© is assessed on a scale of 0 to 4, with higher scores representing greater disability. The index demonstrates sensitivity and specificity in distinguishing between normal subjects and patients with dry eye disease. The OSDI© is a valid and reliable instrument for measuring dry eye disease (normal, mild to moderate, and severe) and effect on vision-related function.
- Glaucoma Symptom Scale (GSS)At baseline and 3-6 months after glaucoma treatment (i.e. drops, SLT, or surgery) was initiated/performed.
The Glaucoma Symptom Scale (GSS; Lee et al., 1998) was developed as a brief symptom survey specific for persons with glaucoma. The GSS consists of a 10-item scale developed from a modified version of a symptom checklist that address ocular complaints, some of a nonvisual nature and some of a visual nature, common to patients with glaucoma. Items are scored from 0 to 100, where 100 represents the absence of symptoms and 0 represents severe, bothersome symptoms.
- National Eye Institute Visual Function Questionaire (NEI VFQ)At baseline and 3-6 months after glaucoma treatment (i.e. drops, SLT, or surgery) was initiated/performed.
Vision-specific instrument designed to measure vision-related quality of life (VRQoL) in adults, incorporating body, activity, and participation content according to the WHO ICF Framework in order to measure the effects of a variety of ocular conditions on daily functioning and QOL. It was originally designed as a 51-point questionnaire and is currently available in both self-administered and interview-based formats. The raw scores are converted to a 0-100 scale; after reverse scoring, a high score (100) indicates better vision-specific quality of life, while a low score (0) indicates poor function.
- Glaucoma Quality of Life-15 (GQL-15)At baseline and 3-6 months after glaucoma treatment (i.e. drops, SLT, or surgery) was initiated/performed.
The Glaucoma Quality of Life-15 (GQL-15) is a validated 15-item, self-report questionnaire used to measure visual disability and quality of life (QoL) in glaucoma patients. It covers four key areas-peripheral vision, central/near vision, glare/dark adaptation, and outdoor mobility-using a 5-point scale (1=no difficulty to 5=severe difficulty).